Company Overview and News

 
WICET appoints Fort Street in coal restructure

2016-06-02 theage.com.au
The Wiggins Island Coal Export Terminal (WICET), part-owned by Australia's biggest coal miner, Glencore, has tapped Fort Street Advisers to help devise a $2 billion-plus restructuring plan for the debt-laden facility.

 
WICET appoints Fort Street in coal restructure

2016-06-02 smh.com.au
The Wiggins Island Coal Export Terminal (WICET), part-owned by Australia's biggest coal miner, Glencore, has tapped Fort Street Advisers to help devise a $2 billion-plus restructuring plan for the debt-laden facility.

 
Aurizon takes WICET fight with coal miners to Queensland Supreme Court

2016-03-18 theage.com.au
Aurizon is taking a battle with Queensland coal miners to the Supreme Court after failing to resolve a dispute with the owners of WICET.

 
Aurizon takes WICET fight with coal miners to Queensland Supreme Court

2016-03-18 smh.com.au
Aurizon is taking a battle with Queensland coal miners to the Supreme Court after failing to resolve a dispute with the owners of WICET.

 
Glencore, partners in Australian port face heavy cost of boom era bet

2016-03-17 straitstimes
MELBOURNE (REUTERS) - Glencore and five other miners backing the world's most expensive coal port in Australia face extra annual charges of A$150 million (S$154 million) after the restructuring of one of their partners this month, the latest to buckle under slumping commodity prices.

 
Cockatoo Coal restructure leaves Aurizon and WICET in the loop

2016-03-09 australianmining.com.au
Aurizon is set to lose $100 million in revenues after Cockatoo Coal failed to fulfill the terms of its contracts with the Wiggins Island Coal Export Terminal.

 
Final 2015 Asset Class Results

2016-01-06 seekingalpha
Some might call the performance of the different asset classes we track a wash in 2015, as six of the top eight strategies finished within roughly 4% of each ot

 
Recapping 2015: The Year In Treasury Inflation-Protected Securities

2016-01-05 seekingalpha
TIPS lost value in 2015 as investors shunned inflation protection.The TIP ETF finally fell below the $110 level, a positive signal?The TIPS market is more attra

 
Sale of Dingo West Coal Project

2015-11-02 asx.com.au

 
Quarterly Activities Report

2015-10-29 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...